ArticleNPJ biofilms and microbiomes2026
Phage therapy targeting DNA-encapsulated membrane vesicle-producing intestinal symbiotic Klebsiella pneumoniae ameliorates autoimmune disease.
Article in NPJ biofilms and microbiomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Autoimmune hepatitis (AIH) is a progressive and currently incurable inflammatory liver disorder. Accumulating evidence suggests that intestinal Klebsiella pneumoniae may contribute to AIH. However, the specific bacterial features underlying its role remain unclear. We isolated 32 strains of K. pneumoniae from both healthy and AIH patients. Genomic and phenotypic analyses identified a unique strain, KpA4-1 from an AIH patient, distinguished by its production of membrane vesicles (MVs) encapsulating plasmid DNA (p2). Administration of p2-containing MVs in mice elevated serum liver enzymes and antinuclear antibodies (ANA), indicating liver injury and autoimmune activation. Oral administration of KpA4-1 in AIH mice exacerbated AIH pathology, evidenced by elevated liver enzymes, increased ANA titers, and enhanced hepatic CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.